



Epilepsy Pipeline Review
Friday, April 17th in conjunction with the **10th Antiepileptic Drugs Conference**
 Biltmore Hotel, 1200 Anastasia Avenue, Coral Gables, Florida 33134, tel 800-915-1926

Later Stage Pipeline

Moderator: Harvey Kupferberg, PhD

Phase III

8:15-8:30	Responsive Neurostimulation System	Neuropace	Martha Morrell, MD
8:30-8:45	Brivaracetam	UCB Pharma	Philipp von Rosenstiel, MD
8:45-9:00	Carisbamate	Johnson and Johnson PRD	Gerald Novak, MD
9:00-9:15	Eslicarbazepine	Sepracor	Mark Versavel, MD
9:15-9:30	Intranasal Midazolam	Intranasal Inc	Jeff Edelson, MD
9:30-9:45	Modif Release Oxcarbazepine	Supernus	Paolo Baroldi, MD, PhD
9:45-10:00	Retigabine	Valeant Pharmaceuticals	Hank Mansbach, MD
10:00-10:20	BREAK		
10:20-10:35	Vigabatrin	Ovation Pharmaceuticals	Stephen Sagar, MD
10:35-10:50	Clobazam	Ovation Pharmaceuticals	Mark Weinberg, MD

Phase II

10:50-11:05	Ganaxalone	Marinus Pharmaceuticals	Julia Tsai, PhD
11:05-11:20	ICA-105665	lcagen	Greg Rigdon, PhD
11:20-11:35	Perampanel (E2007)	Eisai Medical Research, Inc.	David Squillacote, MD
11:35-11:50	T2000: Non sedating barbiturates	Taro	Daniel Moros, MD
11:55-12:10	YKP3089	SK Life Sciences	S. James Lee, PhD
12:10-12:25	VPA: 2 nd Generation Drugs	Hebrew Univ. of Jerusalem	Meir Bialer, PhD, MBA

12:25-1:25 **Lunch**

Early Stage Pipeline

Moderator: Joyce Cramer, Epilepsy Therapy Project

1:25-2:25 **Panel:**

Public, Private Equity & Industry Perspectives on Financing New Therapies in Epilepsy & CNS: Finding the Money in 2009

- Chair: Frank Fisher, Neuropace
- Nicole Vitullo: Biotech VC/crossover, Domain Associates
- Omar Amirana: Device-focus VC, Oxford Bioscience Partners
- Tim Coan: Institutional investor, Deerfield Management Co
- Markus Goebel, Pharma VC, Novartis Ventures
- Nancy Santilli: Commercial development, Endo Pharmaceuticals
- Michael King: Healthcare banking, Rodman & Renshaw (invited)

2:25-2:40 Break

Phase 1

2:40	Huperzine	Harvard	Steven Schachter, MD
2:50	NPY gene transfer	Neurologix	Christine Sapan, Matt During MD
3:00	Neural Plasticity: 2DG	NeuroGenomeX	Thomas Sutula, MD, PhD
3:10	Drug Delivery Pump	Sierra Neuropharmaceuticals	Daniel Abrams, MD
3:20	Drug Delivery System	New York University	Orrin Devinsky, MD
3:30	Seizure detection/prevention	NeuroVista	John Harris, PhD



EPILEPSY THERAPY PROJECT
*A non-profit organization advancing new therapies for
people living with epilepsy*

Epilepsy Pipeline Review

Friday, April 17th in conjunction with the **10th Antiepileptic Drugs Conference**
Biltmore Hotel, 1200 Anastasia Avenue, Coral Gables, Florida 33134, tel 800-915-1926

Pre-Clinical

3:40	New molecular entity	NeuroTherapeutics Pharma	Stephen Collins MD,PhD
3:50	Galanin NTX 5055	Neuroadjuvants	Steve White, PhD
4:00	AMP-X-001, 026	AurimMed Pharma	Manny Balandrin, PhD
4:10	Magnetonanoparticles for MRI	Epinano	Massoud Akhtari, PhD
4:20	Intranasal lorazepam NanoCrystal	Neurelis	Craig Chambliss, PhD
4:30	Convection-enhanced toxin delivery	MedGenesis Therapeutix	Michael Rogawski MD,PhD
4:40	GAERS, MTLE mouse models	Synapcell	Corrine Roucard PhD

Summary

4:50	The role of Epilepsy Therapy Project in supporting the future	Warren Lammert
------	---	----------------